Celldex Therapeutics, Inc. (NasdaqCM: CLDX)
Health Care · Biotechnology · US
$29.50
-1.30% today · +8.5% 1Y
Celldex Therapeutics, Inc. (NasdaqCM: CLDX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.35B and employs 198 people.
Over the last twelve months the share price has gained 8.5%, trading between 22.10 and 45.14.
Tweenvest scores Celldex Therapeutics, Inc. across four factors: quality 38/100, value 40/100, growth 0/100. Its strongest factor is value.
CLDX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.35B
- Revenue (TTM)
- $158.00K
- P/E
- —
- EPS
- -4.33
- Dividend yield
- —
- Beta (5Y)
- 0.90
- 52-week high
- $45.14
- 52-week low
- $22.10
- Avg volume (3M)
- —
- Shares outstanding
- 78.53M
- Employees
- 198
- Next earnings
- —
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
- ISIN
- US15117B2025
- Listed since
- May 15, 1986
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sinocelltech Group LimitedSHSE: 688520 | $2.54B | CN¥36.22 | -2.24% |
| Zealand Pharma A/SCPSE: ZEAL | $2.43B | Dkr234.80 | -1.34% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.38B | $61.20 | -1.39% |
| SELLAS Life Sciences Group, Inc.NasdaqCM: SLS | $2.35B | $11.89 | +2.06% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.34B | $3.95 | -9.52% |
| PharmaResearch Co., Ltd.KOSDAQ: A214450 | $2.34B | ₩302,500.00 | -1.14% |
| ADMA Biologics, Inc.NasdaqGM: ADMA | $2.32B | $10.29 | -0.68% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $2.32B | $22.06 | -1.32% |
Figures last refreshed Oct 11, 2026.